CA2850999C - Method for the treatment of hypertriglyceridemia - Google Patents

Method for the treatment of hypertriglyceridemia Download PDF

Info

Publication number
CA2850999C
CA2850999C CA2850999A CA2850999A CA2850999C CA 2850999 C CA2850999 C CA 2850999C CA 2850999 A CA2850999 A CA 2850999A CA 2850999 A CA2850999 A CA 2850999A CA 2850999 C CA2850999 C CA 2850999C
Authority
CA
Canada
Prior art keywords
calebin
fat
kcal
group
fat diet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2850999A
Other languages
English (en)
French (fr)
Other versions
CA2850999A1 (en
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Anju Majeed
Sarang Bani
Anjali Pandey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2963383A priority Critical patent/CA2963383C/en
Publication of CA2850999A1 publication Critical patent/CA2850999A1/en
Application granted granted Critical
Publication of CA2850999C publication Critical patent/CA2850999C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2850999A 2014-04-23 2014-05-01 Method for the treatment of hypertriglyceridemia Active CA2850999C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2963383A CA2963383C (en) 2014-04-23 2014-05-01 Method for the treatment of hypercholesterolemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/259,404 2014-04-23
US14/259,404 US9668999B2 (en) 2014-04-23 2014-04-23 Method for the treatment of hypercholesterolemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2963383A Division CA2963383C (en) 2014-04-23 2014-05-01 Method for the treatment of hypercholesterolemia

Publications (2)

Publication Number Publication Date
CA2850999A1 CA2850999A1 (en) 2015-10-23
CA2850999C true CA2850999C (en) 2018-04-03

Family

ID=50828681

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2850999A Active CA2850999C (en) 2014-04-23 2014-05-01 Method for the treatment of hypertriglyceridemia
CA2963383A Active CA2963383C (en) 2014-04-23 2014-05-01 Method for the treatment of hypercholesterolemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2963383A Active CA2963383C (en) 2014-04-23 2014-05-01 Method for the treatment of hypercholesterolemia

Country Status (11)

Country Link
US (2) US9668999B2 (https=)
EP (1) EP2937084B1 (https=)
JP (1) JP6263707B2 (https=)
KR (1) KR101647549B1 (https=)
AU (1) AU2014202312B2 (https=)
CA (2) CA2850999C (https=)
EA (1) EA027148B1 (https=)
MY (1) MY170067A (https=)
PH (1) PH12014000244A1 (https=)
PL (1) PL2937084T3 (https=)
TW (1) TWI622394B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201503805XA (en) * 2015-04-19 2016-11-29 Sabinsa Corp Calebin A For Hepatic Steatosis
US9539232B1 (en) * 2016-08-04 2017-01-10 Muhammed Majeed Calebin A for osteoporosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1060352C (zh) * 1996-02-08 2001-01-10 袁克兴 降脂药及其制备方法
US6811786B1 (en) * 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
AU2300001A (en) * 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
US20020012733A1 (en) 2000-04-12 2002-01-31 The Procter & Gamble Company Compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels
JP2005232059A (ja) * 2004-02-18 2005-09-02 Iichiro Shimomura 低アディポネクチン血症予防・治療剤
JP4834824B2 (ja) * 2004-07-08 2011-12-14 独立行政法人産業技術総合研究所 アディポネクチン産生増強剤
JP2010018522A (ja) * 2007-03-23 2010-01-28 Hiroshima Univ アディポネクチン産生促進剤
JP5294165B2 (ja) * 2007-03-23 2013-09-18 ナガセケムテックス株式会社 アディポネクチン上昇剤
CN101301455A (zh) * 2008-07-01 2008-11-12 崔井朝 一种治疗高脂血症的中药复方姜黄固体分散体
JP2011063543A (ja) * 2009-09-17 2011-03-31 Kao Corp アディポネクチン増加剤
US8577013B1 (en) * 2011-01-10 2013-11-05 West Corporation Automatic communications forwarding to displaced employees

Also Published As

Publication number Publication date
US9610273B2 (en) 2017-04-04
CA2963383A1 (en) 2015-10-23
EP2937084B1 (en) 2016-11-30
US20150306060A1 (en) 2015-10-29
TWI622394B (zh) 2018-05-01
US20150306059A1 (en) 2015-10-29
PL2937084T3 (pl) 2017-05-31
US9668999B2 (en) 2017-06-06
TW201540295A (zh) 2015-11-01
EA201491545A1 (ru) 2015-10-30
MY170067A (en) 2019-07-03
EA027148B1 (ru) 2017-06-30
JP6263707B2 (ja) 2018-01-24
CA2963383C (en) 2018-12-04
JP2015209424A (ja) 2015-11-24
KR101647549B1 (ko) 2016-08-10
AU2014202312B2 (en) 2018-02-22
HK1210590A1 (en) 2016-04-29
CA2850999A1 (en) 2015-10-23
PH12014000244B1 (en) 2016-08-08
EP2937084A1 (en) 2015-10-28
NZ624269A (en) 2014-12-24
KR20150122552A (ko) 2015-11-02
AU2014202312A1 (en) 2015-11-12
PH12014000244A1 (en) 2016-08-08

Similar Documents

Publication Publication Date Title
Sharma et al. Therapeutic value of camel milk–a review
Newbury et al. Malnutrition in older people: screening and management strategies
CA2850999C (en) Method for the treatment of hypertriglyceridemia
CN1827618A (zh) 一类异喹啉衍生物、制备方法及用途
Mirtha et al. The effect of foot exercise on diabetic patients with foot ulcer: An Evidence-based case report
NZ624269B (en) Method for the treatment of hypercholesterolemia
HK1210590B (en) Method for the treatment of hypercholesterolemia
CN114711192A (zh) 一种长效抑郁症动物模型的构建试剂盒及构建方法
JP2017176171A (ja) フコキサンチンをフコキサンチノール及びアマロウシアキサンチンａの形態で蓄積させた鶏卵、及び、それを用いた機能性加工食品、抗肥満材、除脂肪体重増加剤、並びに、鶏卵の産生方法
Pourmand et al. Vitiligo treatment in ancient Iranian Medicine
CA2986941C (en) New use of isoquinoline derivatives for diabetic wound healing
RU2256460C2 (ru) Способ лечения неспецифической бронхопневмонии у телят
CN1857350A (zh) 一种增强免疫功能的药物或保健品及其制备方法
Nisak et al. Effectiveness and Mechanism of Action of Vanadyl Sulfate in Increasing Pancreatic β Cell Proliferation of DM Mice Due to Streptozotocin Induction.
CN1524953A (zh) 抗衰老药物组合物及其制备方法
Bakhti et al. Dorema Aucheri and exercise training in enhancing PPARγ/mTOR/PI3K gene expression in muscle tissue of hypothyroid mice: experimental approaches using a hypothyroid mouse model
Khalid et al. Study of factors influencing the success of foot and mouth disease (FMD) vaccination in beef cattle in North Sumatera Province
CN1370443A (zh) 一种神经节苷脂和豆类食品的组合物及其应用
JP5930814B2 (ja) 肝炎予防又は治療剤
TWI581798B (zh) 用於消耗體脂肪的組合物
CN1530101A (zh) 一种具有净化血液、改善免疫力和调节血脂作用的保健食品组合物
Wedded et al. MARCH 15, Ir" 4 TREATMENTOF PULMONARY-TUBERCULOBIE. T
Alimbuyao et al. Hypocholesterolemic and hypoglycemic effect of saccharum of officinale (sugar cane) peel crude extract in albino mice.
CN109172567A (zh) 马索亚内酯在制备预防和/或治疗自身免疫疾病药物或保健品方面的应用
Saada et al. Efficacy of aqueous and methanol extracts of Randia nilotica against migrating juvenile of Schistosoma mansoni in comparison with praziquantel in mice

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151127

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250417

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250520